1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File No. 0-11472
------------
CUSIP No. 09061T 50 90
------------
(Check One): X Form 10-K and Form 10-KSB __Form 20-F __Form 11-K
__Form 10-Q and Form 10-QSB __Form N-SAR
For Period Ended: December 31, 2000
---------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
--------------------- ---------
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAIN HEREIN.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- -------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
Biomune Systems, Inc.
- ---------------------
Full Name of Registrant
Former Name if Applicable
6502 South Archer Road
- ----------------------
Address of Principal Executive Office (Street and Number)
Bedford Park, Illinois 60501
- ----------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (C)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort
or expense;
[X] (b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report of
transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed
due date; and
[ ] (C) The accountant's statement or other exhibit required by
Rule 12b-25(C) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K and 10-KSB, 20-F,
11-K, 10-Q and 10-QSB, -SAR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
The annual report of the registrant on form 10-KSB could not be filed because of
delays encountered in finalizing the financial information relating to certain
acquisitions in January 2001 needed to complete this report.
2
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Larry Koskan (708) 563-9200
----------------------------------------- ----------- ------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). X Yes No
----- -----
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? Yes X No
----- -----
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
===============================================================================
BIOMUNE SYSTEMS, INC.
----------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 3, 2001 By: /s/ Larry P. Koskan
------------- -------------------------------------------
Larry Koskan, President and
Chief Executive Officer